Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corp (NQ: INCY )

74.12 +0.19 (+0.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,024,275
Open 73.91
Bid (Size) 72.47 (2)
Ask (Size) 75.00 (12)
Prev. Close 73.93
Today's Range 73.28 - 74.67
52wk Range 50.35 - 74.67
Shares Outstanding 222,430,635
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Incyte's Jakafi Demand Is Strong, Analyst Upgrades Stock
Incyte reports strong Q3 earnings, driven by Jakafi growth, prompting BofA upgrade with a new price target of $90. 
Via Benzinga
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio. 
Via Benzinga

Performance

YTD
+13.25%
+13.25%
1 Month
+8.90%
+8.90%
3 Month
+15.06%
+15.06%
6 Month
+39.61%
+39.61%
1 Year
+36.33%
+36.33%

More News

Read More
This Alphabet Analyst Turns Bullish; Here Are Top 5 Downgrades For Wednesday
Via Benzinga
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Incyte Breaks Out To 17-Month High As Jakafi Demand Surges
Via Investor's Business Daily
Peeling Back The Layers: Exploring Incyte Through Analyst Insights
Via Benzinga
Uncovering Noteworthy Technical Analysis Findings for INCYTE CORP (NASDAQ:INCY).
Via Chartmill
A Look Into Incyte Inc's Price Over Earnings
Via Benzinga
Incyte Clocks Mixed Q3 Earnings, But Analyst Sees A Strong Quarter For Jakafi And Opzelura
Via Benzinga
Corning Posts Upbeat Q3 Earnings, Joins Opera, Inari Medical, Incyte And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
Incyte Named One of Top 5 Companies on Science Magazine’s 2024 Top Employers List
From Incyte
Via Business Wire
Assessing Incyte: Insights From 11 Financial Analysts
Via Benzinga
Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program
From Incyte
Via Business Wire
Incyte to Report Third Quarter Financial Results
From Incyte
Via Business Wire
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate
Via Benzinga
Exposures Product Safety
Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress
From Incyte
Via Business Wire
Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Wall Street Lower Ahead Of Interest Rate Move
Via Talk Markets
Intel Leads S&P 500 Monday, And Keeps Running Late; Apple Chipmakers Are Biggest Losers
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer
From Incyte
Via Business Wire
Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium
From Incyte
Via Business Wire
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.